Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about VRTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Suzetrigine FDA approved Jan 2025 · Journavx |
Acute Pain | Phase 4 · NCT06887959 | Completed |
| Ivacaftor FDA approved Jan 2012 · Kalydeco |
Cystic Fibrosis | Phase 3 · NCT06460506 | Active not recruiting |
| Tezacaftor | Cystic Fibrosis | Phase 3 · NCT05422222 | Active not recruiting |
| Povetacicept | Primary Membranous Nephropathy | Phase 2/3 · NCT07204275 | Recruiting |
| multimodal analgesia regimen without suzetrigine | Opioid Consumption, Postoperative | Phase 3 · NCT07654296 | Recruiting |
| Vanzacaftor | Cystic Fibrosis | Phase 3 · NCT05844449 | Enrolling by invitation |
| VX-017 | Diabetes Mellitus, Type 1 | Phase 3 · NCT04786262 | Recruiting |
| VX-147 | Proteinuric Kidney Disease | Phase 2/3 · NCT05312879 | Active not recruiting |
| Exagamglogene Autotemcel (CTX001) | Sickle Cell Disease | Phase 2/3 · NCT03745287 | Completed |
| Elexacaftor | Cystic Fibrosis | Phase 3 · NCT06460506 | Active not recruiting |
| Zimislecel (VX-880) | Diabetes Mellitus, Type 1 | Phase 3 · NCT04786262 | Recruiting |
| VX-993 | Diabetic Peripheral Neuropathic Pain | Phase 2 · NCT06619860 | Recruiting |
| VX-264 | Type 1 Diabetes | Phase 1/2 · NCT05791201 | Active not recruiting |
| VX-407 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2 · NCT07161037 | Active not recruiting |
| VX-522 mRNA therapy | Cystic Fibrosis | Phase 1/2 · NCT05668741 | Completed |
| VX-670 | Myotonic Dystrophy Type 1 (DM1) | Phase 1/2 · NCT06185764 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not VRTX's own candidates): Sibeprenlimab, Pregabalin, Tacrolimus Extended-Release, Efavirenz, Itraconazole, Midazolam Hydrochloride.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
VRTX holds $9.8B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VRTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Capital World Investors | Institution (13G, 5%+) | 25,695,015 | 10.13% | 2026-03-31 |
| Blackrock Inc. | Institution (13F) | 23,803,111 | 9.39% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 19,036,076 | 7.51% | 2026-03-31 |
| Capital Research Global Investors | Institution (13G, 5%+) | 17,821,661 | 7.03% | 2026-09-30 |
| State Street Corporation | Institution (13F) | 12,024,456 | 4.74% | 2026-09-30 |
| Invesco Ltd. | Institution (13F) | 8,280,998 | 3.27% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 6,081,969 | 2.40% | 2026-09-30 |
| JPMORGAN CHASE & CO | Institution (13F) | 5,691,686 | 2.24% | 2026-09-30 |
| Capital International Investors | Institution (13F) | 5,059,186 | 2.00% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 4,944,618 | 1.95% | 2026-09-30 |
| Reshma Kewalramani CEO & President, Director |
Insider | 86,471 | 0.03% | 2026-11-06 |
| Amit Sachdev EVP Chief Patient & Ext Af Off |
Insider | 74,031 | 0.03% | 2026-07-21 |
Share count 253,537,674 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-12 filed 2026-11-16 |
WAGNER CHARLES F JR |
Sale (S) | 15,286 | $547.87 | 31,764 |
| 2026-11-06 filed 2026-11-10 |
Kewalramani Reshma |
Sale (S) | 11,866 | $531.53 | 86,471 |
| 2026-10-20 filed 2026-10-22 |
Brennan Daniel J. |
Award (A) | 795 | $503.47 | 795 |
| 2026-09-08 filed 2026-09-10 |
van Grunsven Jasper |
Award (A) | 8,682 | – | 8,682 |
| 2026-08-28 filed 2026-09-01 |
Ambrose Kristen |
Award (A) | 5,000 | – | 11,624 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VRTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →